Public health insurance and cancer‐specific mortality risk among patients with breast cancer: A prospective cohort study in China by Xie, Yuxin et al.
C AN C E R E P I D EM I O LOG Y
Public health insurance and cancer-specific mortality risk
among patients with breast cancer: A prospective
cohort study in China
Yuxin Xie1,2 | Unnur A. Valdimarsdóttir3,4,5 | Chengshi Wang2 |
XiaoRong Zhong1,2 | Qiheng Gou1 | Hong Zheng1,2 | Ling Deng2 | Ping He1,2 |
Kejia Hu2,6 | Katja Fall7 | Fang Fang6 | Rulla M. Tamimi8 | Ting Luo1,2 |
Donghao Lu1,2,3,9
1Department of Medical Oncology of Cancer
Center, West China Hospital, Sichuan
University, Chengdu, China
2Laboratory of Molecular Diagnosis of Cancer,
Clinical Research Center for Breast, West
China Hospital, Sichuan University, Chengdu,
Sichuan, China
3Department of Medical Epidemiology and
Biostatistics, Karolinska Institutet, Stockholm,
Sweden
4Center of Public Health Sciences, School of
Health Sciences, Faculty of Medicine,
University of Iceland, Reykjavík, Iceland
5Department of Epidemiology, Harvard
T.H. Chan School of Public Health, Boston,
Massachusetts
6Institute of Environmental Medicine,
Karolinska Institutet, Stockholm, Sweden
7Clinical Epidemiology and Biostatistics,
School of Medical Sciences, Örebro University,
Örebro, Sweden
8Department of Population Health Sciences,
Weill Cornell Medicine, New York, New York
9Channing Division of Network Medicine,
Brigham and Women's Hospital, Harvard
Medical School, Boston, Massachusetts
Correspondence
Donghao Lu and Ting Luo, Department of
Medical Oncology of Cancer Center, Clinical
Research Center for Breast, West China
Abstract
Little is known about how health insurance policies, particularly in developing countries,
influence breast cancer prognosis. Here, we examined the association between individ-
ual health insurance and breast cancer-specific mortality in China. We included 7436
women diagnosed with invasive breast cancer between 2009 and 2016, at West China
Hospital, Sichuan University. The health insurance plan of patient was classified as either
urban or rural schemes and was also categorized as reimbursement rate (ie, the covered/
total charge) below or above the median. Breast cancer-specific mortality was the pri-
mary outcome. Using Cox proportional hazards models, we calculated hazard ratios
(HRs) for cancer-specific mortality, contrasting rates among patients with a rural insur-
ance scheme or low reimbursement rate to that of those with an urban insurance
scheme or high reimbursement rate, respectively. During a median follow-up of
3.1 years, we identified 326 deaths due to breast cancer. Compared to patients covered
by urban insurance schemes, patients covered by rural insurance schemes had a 29%
increased cancer-specific mortality (95% CI 0%-65%) after adjusting for demographics,
tumor characteristics and treatment modes. Reimbursement rate below the median was
associated with a 42% increased rate of cancer-specific mortality (95% CI 11%-82%).
Every 10% increase in the reimbursement rate is associated with a 7% (95% CI 2%-12%)
reduction in cancer-specific mortality risk, particularly in patients covered by rural insur-
ance schemes (26%, 95% CI 9%-39%). Our findings suggest that underinsured patients
face a higher risk of breast cancer-specific mortality in developing countries.
Abbreviations: BCIMS, Breast Cancer Information Management System; BMI, body mass index; CIs, confidence intervals; HER2, human epidermal growth factor receptor 2; HR, hazard ratios;
NRCMS, New Rural Cooperative Medical Scheme; OR, odds ratio; SES, socioeconomic status; UEBMI, Urban Employee-based Basic Medical Insurance Scheme; URBMI, Urban Resident-based
Basic Medical Insurance Scheme; WCH, West China Hospital.
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1 | INTRODUCTION
Battling cancer is a crushing burden for all patients, but particularly so
for those who are vulnerable to financial stress. It is common that can-
cer patients experience severe financial stress throughout their
survivorship,1 especially in developing countries where the health sys-
tem is not ready to ease the burden for everyone. Cancer patients
have higher out-of-pocket costs and may be absent from work for
quite a while, which further lowers the ability to pay for medical
care.1,2 As an avalanche of “financial toxicity”—the damaging eco-
nomic side effects of illness, cancer patients are at tremendous risk
for debt, bankruptcy and impaired psychological wellbeing.3,4
It is well-documented that social inequality in health contributes to
the disparities in cancer survivorship in both developed and developing
countries, including China.5-8 The presence of a public health insurance
system seems essential for a country to achieve universal healthcare cov-
erage and health equity.9 Improved health insurance coverage can reduce
sociodemographic disparities in cancer care, including breast cancer,
through early diagnosis and optimal treatment.10,11 Fewer studies have
paid attention to the impact of health insurance on cancer prognosis. So
far, four US studies,11-14 support the hypothesis that underinsured
patients have a worse breast cancer prognosis, but two other studies
from Australia and Brazil reported no clear differences related to the level
of health insurance.15,16 However, it is largely unclear whether the health
insurance policies particularly in developing countries, where the patients
may face higher financial toxicity, influence breast cancer prognosis.
Moreover, all reports have focused on insurance status or types, while no
studies have addressed the out-of-pocket cost as an important barrier to
cancer care.11-16 It is, therefore, of critical importance to understand how
different insurance plans, featured by varying reimbursement rates (ie, the
covered/total charge) within specific insurance type, further contribute to
the disparities in diagnosis, treatment and prognosis of breast cancer.
The health insurance system was first introduced to China mainland
China in 1980s, and drastically expanded to over 95.7% of the total popula-
tion over the past decades.17,18 The majority of insurance system is state-
run, while commercial insurancemay be purchased as a complement. There
are three major state-run schemes of public health insurance in China,
including the new rural cooperative medical scheme (NRCMS, covering the
residents of rural households and launched in 2003), urban resident-based
basic medical insurance scheme (URBMI, covering the unemployed, chil-
dren and elderly and launched in 2007) and urban employee-based basic
medical insurance scheme (UEBMI, covering employees and launched in
1998).17,18 A variety of medical expenditures could be reimbursed by the
public health insurance, and the rest of costswould be paid out of pocket or
by commercial insurance, if any. These costs include, for example, deduct-
ible, coinsurance and certain medical examinations (eg, positron-emission
tomography-computed tomography) and treatment (eg, trastuzumab until
the year of 2018 andCDK4/6 inhibitors).
Leveraging a prospective large-scale cohort of patients with inva-
sive breast cancer in China diagnosed from 2009 to 2016, we aimed
to examine the associations of health insurance types and reimburse-
ment rates with the risks of breast cancer-specific mortality.
2 | MATERIALS AND METHODS
2.1 | Study population
We identified 7623 female patients who were diagnosed with inva-
sive breast cancer at West China Hospital (WCH), Sichuan University
from January 1, 2009, to December 31, 2016, based on the Breast
Cancer Information Management System (BCIMS). The BCIMS covers
virtually all patients with breast cancer diagnosed at WCH since 2008
and prospectively collects information on demographic and clinical
characteristics, laboratory examinations, treatment and follow-up
visits.18 We excluded 37 male patients, three patients due to loss to
follow-up and 147 patients without the information on both types of
health insurance and reimbursement rate, leaving 7436 patients in the
final cohort.
What's new?
Although improved health insurance coverage can reduce
sociodemographic disparities in cancer care, the impact of
health insurance on cancer prognosis is unclear. In a prospec-
tive cohort of breast cancer patients in China, under-insured
patients (insured by rural schemes or with low reimburse-
ment rate) were at increased risk of cancer-specific mortality,
independent of tumor characteristics and primary treatment.
Promoting public health insurance, particularly reimburse-
ment rate, in developing countries may help reduce dispar-
ities in breast cancer survivorship.
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2.2 | Health insurance
Three insurance schemes are administered by different national
institutions and operated by local governments. NRCMS is adminis-
tered by the Chinese National Health and Family Planning Commis-
sion and financed at the county level, while URBMI and UEBMI are
administered by the Chinese Ministry of Human Resources and
Social Security and financed at the municipal (prefecture) level in
2013.19 Thus, the benefit packages and financial support are frag-
mented and inequitable across the schemes. For example, compared
to UEBMI and URBMI, NRCMS is limited to a lower reimbursement
cap and covers a narrower spectrum of diseases. The mean reim-
bursement rate for NRCMS is mainly 50% to 65%, which is much
lower than UEBMI with a rate of 85% to 95%.20,21 The disparities
between urban and rural health insurances are thus considerable.
Therefore, China has been establishing a consolidated health insur-
ance scheme by 2020. For example, the fund pooling and manage-
ment of NRCMS (from county level) and UEBMI and URBMI (from
municipal level) should be moved to provincial and then country
levels. The reimbursement rate is defined as the amount of medical
expenses covered by insurance divided by the total expense. As the
insurance is partly funded by local governments, the reimbursement
rates may vary widely across counties, even under the same insur-
ance scheme. Moreover, the rate is individual-based, affected and
calculated by age, years of employment, hospital level and treatment
modes.
The information on insurance types and reimbursement rates
(for the primary treatment) is routinely documented in BCIMS. Spe-
cifically, the information on the type of insurance is provided by
patients at the registration to BCIMS, while the rate of reimburse-
ment is collected for the primary treatment during follow-up. Given
the different administrations and insurance plans (Supporting
Information Material), we classified insurance types into urban
(ie, URBMI, UEBMI, and/or commercial insurances) and rural
(ie, NRCMS) schemes, respectively. In the analysis of insurance type,
139 patients without any insurance and eight patients of unknown
insurance status were excluded. Our data showed that the reimburse-
ment rate was different among patients insured by urban or rural
schemes (Figure S1). We also classified patients by reimbursement
rate below (0-69%) or above (70%-100%) the median. Patients with-
out insurance were coded as 0 reimbursement rate. Then, 569 patients
(192 insured by rural schemes) were excluded from this analysis due
to unknown reimbursement rate.
2.3 | Breast cancer-specific and overall mortality
All patients were actively followed through telephone contact and
medical visits until death or May 17, 2017, whichever came first. The
underlying cause of death was ascertained from the medical records,
whenever possible, or informed by the immediate family members.
We studied breast cancer-specific mortality as the primary outcome
and overall mortality as the secondary outcome.
2.4 | Statistical analysis
First, we described the demographic and clinical characteristics among
patients with different insurance types and reimbursement rates.
Demographic and clinical characteristics were obtained from BCIMS
and classified as showed in Table 1. We examined the associations of
health insurance type and reimbursement rate with different treatment
modes, using logistic regression with adjustment for demographic and
clinical characteristics. To account for correlations between treatment
types, we additionally adjusted for other types of treatment.
We examined the associations of health insurance type and reim-
bursement rate with different treatment modes, using logistic regres-
sion with adjustment for demographic and clinical characteristics. To
account for correlations between treatment types, we additionally
adjusted for other types of treatment.
Next, we calculated and plotted the cumulative rates and 95%
confidence intervals (CIs) of breast cancer-specific and overall mortal-
ity by insurance type and reimbursement rate up to 5 years after can-
cer diagnosis using a competing risk model.21 Hazard ratios (HRs) and
95% CIs of breast cancer-specific and overall mortality were then esti-
mated from Cox regression by contrasting patients insured by the
rural scheme to patients insured by the urban scheme, as well as
patients with low reimbursement rate to those with high. The propor-
tional hazards assumption, tested based on Schoenfeld residuals, was
not violated. To illustrate the joint effect of insurance type and reim-
bursement rate, we further examined the association of every 10%
increase in reimbursement rate with mortality risks by insurance type.
In Model A, we adjusted for demographic factors, including age
(as a continuous variable), calendar year at diagnosis, ethnic group,
educational level (as a proxy for socioeconomic status, SES) and mari-
tal status. In Model B, we additionally adjusted for clinical characteris-
tics (as potential mediators), including comorbidity, histological type,
tumor stage, hormone receptor status (including both estrogen and
progesterone receptors), HER2 status and Ki-67 level. In Model C, we
additionally controlled for treatment modes, namely surgery, chemo-
therapy, radiotherapy, hormonal therapy and trastuzumab therapy.
Age was treated as continuous variables, whereas other covariates
were categorized as showed in Table 1.
Because body mass index (BMI) would be neither the cause nor
consequence of different insurances, we did not adjust for it in the
primary analysis. We, however, noted that patients with different
insurance were characterized by different BMI. We, therefore, per-
formed an additional analysis by adjusting for BMI at diagnosis.
According to the recommendation for Asian populations,22 we classi-
fied BMI into <23 kg/m2 (nonoverweight) and ≥23 kg/m2 (over-
weight). SES and accessibility to medical service are highly correlated
with individual insurance plans. To further disentangle the potential
influence of SES and accessibility to health-care, we performed a sen-
sitivity analysis by clustering patients residing in the same commu-
nity/county through the zip code of residence.
All analyses were performed in STATA statistical software (ver-
sion 14; STATA, College Station, Texas). Value of P < .05 indicated
statistical significance.
30 XIE ET AL.
TABLE 1 Characteristics of patients with invasive breast cancer by insurance type and reimbursement rate
By insurance type By reimbursement rate









n (%) n (%) n (%) P n (%) n (%) P
Age at diagnosis, years .05 .05
18-39 1276 (17.2) 876 (16.4) 365 (18.6) 581 (16.2) 580 (17.7)
40-49 3145 (42.3) 2102 (39.5) 975 (49.7) 1414 (39.4) 1517 (46.3)
≥50 3015 (40.6) 2349 (44.1) 622 (32) 1593 (44.4) 1182 (36.0)
Calendar year at diagnosis .05 .05
2009-2012 3419 (46.0) 2485 (46.7) 853 (43.5) 1514 (42.2) 1588 (48.4)
2013-2016 4017 (54.0) 2842 (53.3) 1109 (56.5) 2074 (57.8) 1691 (51.6)
Ethnic groups .05
Han 7278 (97.9) 5228 (98.1) 1909 (97.3) 3527 (98.3) 3197 (97.5)
Minority 155 (2.1) 97 (1.8) 53 (2.7) 60 (1.6) 81 (2.4)
Unknown 3 (0.1) 2 (0.1) 0 (0.0) 1 (0.1) 1 (0.1)
Education (years) .05 .05
≤6 1326 (17.8) 587 (11.0) 707 (36.0) 389 (10.8) 799 (24.4)
7-9 2739 (36.8) 1689 (31.7) 986 (50.2) 1091 (30.4) 1428 (43.6)
10-12 1583 (21.3) 1359 (25.5) 200 (10.2) 878 (24.5) 594 (18.1)
>12 1763 (23.7) 1671 (31.4) 68 (3.5) 1219 (34.0) 450 (13.7)
Unknown 25 (0.4) 21 (0.4) 1 (0.1) 11 (0.3) 8 (0.2)
Marital status .05
Married 7253 (97.5) 5168 (97.0) 1942 (98.9) 3490 (97.3) 3208 (97.8)
Nonmarried 183 (2.5) 159 (3.0) 20 (1.1) 98 (2.7) 71 (2.2)
BMI, kg/m2 .05 .05
<23 3806 (51.2) 2869 (53.9) 870 (44.3) 1943 (54.2) 1591 (48.5)
≥23 3602 (48.4) 2440 (45.8) 1085 (55.3) 1633 (45.5) 1680 (51.3)
Unknown 28 (0.4) 18 (0.3) 7 (0.4) 12 (0.3) 8 (0.2)
Menopausal status .05 .05
Premenopausal 4523 (60.8) 3054 (57.3) 1361 (69.4) 2028 (56.5) 2146 (65.5)
Postmenopausal 2893 (38.9) 2258 (42.4) 597 (30.4) 1554 (43.3) 1126 (34.3)
Unknown 20 (0.3) 15 (0.3) 4 (0.2) 6 (0.2) 7 (0.2)
Comorbidity .05 .05
No 6719 (90.4) 4786 (89.8) 1803 (91.9) 3220 (89.7) 2985 (91.0)
Yes 717 (9.6) 541 (10.2) 159 (8.1) 368 (10.3) 294 (9.0)
Hormone receptor status .05
Negative 1867 (25.1) 1323 (24.8) 516 (26.3) 835 (23.3) 887 (27.1)
Positive 5229 (70.3) 3747 (70.3) 1372 (69.9) 2608 (72.7) 2257 (68.8)
Unknown 340 (4.6) 257 (4.9) 74 (3.8) 145 (4.0) 135 (4.1)
HER2 status .05 .05
Negative 4155 (55.9) 3033 (56.9) 1047 (53.4) 2060 (57.4) 1793 (54.7)
Positive 1680 (22.6) 1183 (22.2) 460 (23.4) 811 (22.6) 762 (23.2)
Unknown 1601 (21.5) 1111 (20.9) 455 (23.2) 717 (20.0) 724 (22.1)
Ki-67 level .05 .05
<14% 1301 (17.5) 975 (18.3) 296 (15.1) 665 (18.5) 541 (16.5)
≥14% 5507 (74.1) 3906 (73.3) 1501 (76.5) 2673 (74.5) 2457 (74.9)
Unknown 628 (8.5) 446 (8.4) 165 (8.4) 250 (7.0) 281 (8.6)
(Continues)
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3 | RESULTS
3.1 | Patients’ characteristics
About 1962 (26.9% of 7289 patients with known insurance type)
were insured by rural schemes, and 3279 (47.8% of 6867 patients
with known reimbursement rate) were reimbursed ≤69% of their
healthcare cost. Patients insured by rural schemes were younger and
diagnosed more recently. They were less likely to be Han people, less
well-educated, nonmarried and postmenopausal, as well as with lower
BMI and fewer comorbidities at diagnosis (all P < .05; Table 1). Their
tumors were more likely to be HER2-positive, highly proliferative (Ki-
67 ≥ 14%), poorly differentiated, and to have an advanced stage and
ductal origin. Similar patterns were found for patients with reimburse-
ment rate ≤69%. Underinsured patients were less treated by radio-
therapy, hormonal therapy and trastuzumab, independent of tumor
characteristics and other types of treatment (Table 2). In addition,
patients with low reimbursement rate were less likely to undergo
surgery, whereas patients insured by rural schemes were more likely
to receive chemotherapy.
3.2 | Health insurance and breast cancer-specific
mortality
During follow-up (median 3.1 years, interquartile range 1.4-5.1 years),
372 deaths were observed and 326 of them were due to breast cancer.
The cumulative rates of breast cancer-specific mortality were higher
among patients insured within rural insurance schemes and with reim-
bursement rates ≤69%, compared to patients with urban insurance
schemes and higher reimbursement rates, respectively (Figure 1). Simi-
lar patterns were noticed for overall mortality.
When adjusting for demographic characteristics, patients insured by
rural insurance schemes had a 46% increased risk of cancer-specific mor-
tality (95% CI 14%-87%) compared to patients within urban insurance
schemes (Table 3). With additional control for clinical characteristics and
TABLE 1 (Continued)
By insurance type By reimbursement rate









n (%) n (%) n (%) P n (%) n (%) P
Molecular subtype .05
Luminal A 603 (8.1) 456 (8.6) 129 (6.6) 325 (9.1) 239 (7.3)
Luminal B 3968 (53.4) 2817 (52.9) 1071 (54.6) 1985 (55.3) 1725 (52.6)
HER2 positive 728 (9.8) 514 (9.7) 200 (10.2) 343 (9.6) 334 (10.2)
Triple-negative 863 (11.6) 623 (11.7) 230 (11.7) 391 (10.9) 410 (12.5)
Unknown 1274 (17.1) 917 (17.2) 332 (16.9) 544 (15.1) 571 (17.4)
Tumor stage .05 .05
I 1406 (18.9) 1107 (20.8) 271 (13.8) 753 (21.0) 572 (17.4)
II 3182 (42.8) 2300 (43.2) 820 (41.8) 1565 (43.5) 1385 (42.2)
III 1713 (23.1) 1147 (21.5) 531 (27.1) 791 (22.1) 771 (23.6)
IV 180 (2.4) 119 (2.2) 56 (2.9) 89 (2.5) 90 (2.7)
Unknown 955 (12.8) 654 (12.3) 284 (14.4) 390 (10.9) 461 (14.1)
Histological type .05
Ductal 6897 (92.8) 4910 (92.2) 1849 (94.2) 3321 (92.6) 3076 (93.8)
Others 308 (4.1) 228 (4.3) 75 (3.9) 158 (4.4) 125 (3.8)
Unknown 231 (3.1) 189 (3.5) 38 (1.9) 109 (3.0) 78 (2.4)
Histological grade .05 .05
I 194 (2.6) 152 (2.9) 34 (1.7) 96 (2.7) 87 (2.7)
II 2216 (29.8) 1628 (30.6) 549 (28.0) 1154 (32.2) 933 (28.4)
III 3134 (42.2) 2212 (41.5) 868 (44.2) 1492 (41.5) 1412 (43.1)
Unknown 1892 (25.4) 1335 (25.0) 511 (26.1) 846 (23.6) 847 (25.8)
Note: Patients with missing information on insurance type (n = 147, 1.98%) or reimbursement rate (n = 569, 7.65%) were not included for the
corresponding analysis. Body mass index (BMI) was classified into <23 kg/m2 (non-overweight) and ≥23 kg/m2 (overweight). Tumor stage was categorized
as localized (no nodal or metastatic disease), regional (nodal disease), or distant (any metastatic disease). Pearson's χ2 statistic was used to assess signifi-
cance of the difference between proportions in assessment of univariable associations.
Abbreviation: HER2, human epidermal growth factor receptor 2.
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Model Aa Model Bb Model Cc
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Surgery
By insurance type
Urban schemes 5327 5130 96.3 1.00 1.00 1.00
Rural schemes 1962 1846 94.1 0.65 (0.50-0.83) .001 0.71 (0.54-0.92) .015 0.85 (0.65-1.13) .261
By reimbursement rate
70%-100% 3588 3471 96.7 1.00 1.00 1.00
0%-69% 3279 3116 95.0 0.62 (0.49-0.80) <.001 0.67 (0.51-0.87) .003 0.75 (0.57-0.98) .038
Chemotherapy
By insurance type
Urban schemes 5327 4913 92.2 1.00 1.00 1.00
Rural schemes 1962 1865 95.1 1.56 (1.22-1.98) <.001 1.36 (1.04-1.78) .010 1.40 (1.06-1.83) .016
By reimbursement rate
70%-100% 3588 3335 93.0 1.00 1.00 1.00
0%-69% 3279 3091 94.3 1.16 (0.95-1.42) .140 1.14 (0.91-1.42) .263 1.15 (0.92-1.45) .214
Radiotherapy
By insurance type
Urban schemes 5327 1694 31.8 1.00 1.00 1.00
Rural schemes 1962 560 28.5 0.87 (0.77-0.98) .048 0.72 (0.63-0.83) <.001 0.77 (0.67-0.88) <.001
By reimbursement rate
70%-100% 3588 1193 33.3 1.00 1.00 1.00
0%-69% 3279 984 30.0 0.84 (0.76-0.94) .002 0.78 (0.69-0.88) <.001 0.81 (0.72-0.91) .001
Hormonal therapy
By insurance type
Urban schemes 5327 3546 66.6 1.00 1.00 1.00
Rural schemes 1962 1154 58.8 0.71 (0.63-0.80) <.001 0.62 (0.53-0.72) <.001 0.67 (0.57-0.79) <.001
By reimbursement rate
70%-100% 3588 2464 68.7 1.00 1.00 1.00
0%-69% 3279 2041 62.2 0.74 (0.67-0.82) <.001 0.74 (0.63-0.86) <.001 0.79 (0.68-0.93) .004
Use of trastuzumab
By insurance type
Urban schemes 5327 523 9.8 1.00 1.00 1.00
Rural schemes 1962 80 4.1 0.44 (0.34-0.56) <.001 0.33 (0.25-0.43) <.001 0.33 (0.28-0.49) <.001
By reimbursement rate
70%-100% 3588 374 10.4 1.00 1.00 1.00
0%-69% 3279 221 6.7 0.70 (0.59-0.83) <.001 0.57 (0.47-0.70) <.001 0.68 (0.66-0.89) .006
Note: Patients with missing information on insurance type (n = 147, 1.98%) or reimbursement rate (n = 569, 7.65%) were not included for the
corresponding analysis.
Abbreviations: CI, confidence interval; OR, odds ratio.
aORs were adjusted for age at diagnosis, calendar year at diagnosis (2009-2012 or 2013-2016), ethnic group (majority or minority/unknown), education
(>6 years, or ≤6 years/unknown) and marital status (married or nonmarried).
bORs were additionally adjusted for comorbidity (no or yes), hormone receptor status (negative, positive or unknown), HER2 status (negative, posi-
tive or unknown), Ki-67 level (<14%, ≥14% or unknown), histological type (ductal or other types/unknown) and tumor stage (I, II, III, IV or
unknown).
cORs were additionally adjusted for treatment types, whenever applicable, including surgery (yes or no), chemotherapy (yes or no), radiotherapy (yes or no),
hormonal therapy (yes or no) or trastuzumab therapy (yes or no).
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Model Aa Model Bb Model Cc
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Breast cancer-specific mortality
By insurance type
Urban schemes 5327 211 1.16 1.00 1.00 1.00
Rural schemes 1962 109 1.84 1.46 (1.14-1.87) .003 1.32 (1.03-1.69) .028 1.29 (1.00-1.65) .046
By reimbursement rate
70%-100% 3588 115 0.97 1.00 1.00 1.00
0%-69% 3279 172 1.52 1.60 (1.25-2.04) <.001 1.56 (1.22-1.99) <.001 1.42 (1.11-1.2) <.005
Overall mortality
By insurance type
Urban schemes 5327 248 1.37 1.00 1.00 1.00
Rural schemes 1962 118 1.99 1.41 (1.11-1.78) .004 1.30 (1.03-1.64) .028 1.27 (1.01-1.61) .045
By reimbursement rate
70%-100% 3588 124 1.04 1.00 1.00 1.00
0%-69% 3279 192 1.70 1.68 (1.33-2.12) <.001 1.66 (1.32-2.10) <.001 1.52 (1.20-1.93) <.001
Note: Patients with missing information on insurance type (n = 147, 1.98%) or reimbursement rate (n = 569, 7.65%) were not included for the
corresponding analysis.
Abbreviations: CI, confidence interval; HR, hazard ratio; Rate, mortality rate (per 100 person-years).
aHRs were adjusted for age at diagnosis, calendar year at diagnosis, ethnic group (majority or minority/unknown), education (>6 years, or ≤6 years/
unknown) and marital status (married or nonmarried).
bHRs were additionally adjusted for comorbidity (no or yes), hormone receptor status (negative, positive or unknown), HER2 status (negative, positive or
unknown), Ki-67 level (<14%, ≥14% or unknown), histological type (ductal or other types/unknown) and tumor stage (I, II, III, IV or unknown).
cHRs were additionally adjusted for surgery (yes or no), chemotherapy (yes or no), radiotherapy (yes or no), hormonal therapy (yes or no) and trastuzumab
therapy (yes or no).
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treatment modes, the association was attenuated somewhat yet
remained significant (HR 1.29, 95% CI 1.00-1.65). Similarly, patients with
low reimbursement rate had a 42% increased risk of cancer-specific mor-
tality (95% CI 11%-82%) compared to patients within high reimburse-
ment rate. Similar patterns were found for overall mortality (Table 3).
Largely similar results were yielded for both insurance type
and reimbursement rate after additional control for BMI (Table S1).
Comparable but less significant associations were observed by condi-
tioning on residential areas to further address SES and accessibility to
care (Table S2).
3.3 | Joint effect of insurance type and
reimbursement rate
We showed that every 10% increase in the reimbursement rate was
associated with a 7% reduced risk of cancer-specific mortality (95% CI
2%-12% after full adjustment; Table 4). Particularly, every 10%
increase of reimbursement rate in rural insurance schemes was associ-
ated with remarkable risk reduction of cancer-specific mortality
(HR 0.74, 95% CI 0.61-0.91), compared to that in urban insurance
schemes (HR 0.94, 95% CI 0.86-1.03, P for difference = .039). Similar
results were found in overall mortality (Table 4).
4 | DISCUSSION
To the best of our knowledge, this is the first study to demonstrate
that underinsured patients with invasive breast cancer are at
increased risk of cancer-specific mortality in a country with less devel-
oped health insurance system. Importantly, our findings strongly sug-
gest that a higher reimbursement rate, particularly in rural scheme
insurance, is associated with a remarkable risk reduction of breast
cancer-specific mortality. These associations are partly but not
entirely explained by known prognostic indicators, including tumor
characteristics and cancer treatment.
Findings from several studies in developed countries, mostly from
the US, have shown that underinsured patients with breast cancer are
more likely to suffer an increased risk of cancer-specific mortality,
compared to those with adequate insurance.10-13 Only one study from
developing countries showed that breast cancer prognosis is com-
parable between patients insured by public and private health





Model Aa Model Bb Model Cc
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Breast cancer-specific mortality
Any insurance type
Per 10% increase 6867 287 1.33 0.90 (0.86-0.95) <.001 0.91 (0.87-0.96) 0.001 0.93 (0.88-0.98) .008
Within urban schemes
Per 10% increase 4993 191 1.16 0.92 (0.84-1.00) .078 0.91 (0.83-1.00) 0.052 0.94 (0.86-1.03) .215
Within rural schemes
Per 10% increase 1743 92 1.84 0.70 (0.58-0.84) <.001 0.73 (0.60-0.89) 0.002 0.74 (0.61-0.91) .004
P for differenced 0.007 0.039 0.039
Overall mortality
Any insurance type
Per 10% increase 6867 316 1.52 0.90 (0.86-0.95) <.001 0.91 (0.86-0.95) <0.001 0.92 (0.88-0.97) .002
Within urban schemes
Per 10% increase 4993 214 1.37 0.89 (0.83-0.98) .014 0.89 (0.82-0.97) 0.008 0.92 (0.84-1.00) .051
Within rural schemes
Per 10% increase 1743 98 1.99 0.72 (0.60-0.85) <.001 0.75 (0.62-0.90) 0.002 0.76 (0.63-0.92) .005
P for differenced 0.016 0.087 0.087
Note: Patients with missing information on insurance type (n = 147, 1.98%) or reimbursement rate (n = 569, 7.65%) were not included for the
corresponding analysis.
Abbreviations: CI, confidence interval; HR, hazard ratio; Rate, mortality rate (per 100 person-years).
aHRs were adjusted for age at diagnosis, calendar year at diagnosis, ethnic group (majority or minority/unknown), education (>6 years or ≤6 years/
unknown) and marital status (married or nonmarried).
bHRs were additionally adjusted for comorbidity (no or yes), hormone receptor status (negative, positive or unknown), HER2 status (negative, positive or
unknown), Ki-67 level (<14%, ≥14% or unknown), histological type (ductal or other types/unknown) and tumor stage (I, II, III, IV or unknown).
cHRs were additionally adjusted for surgery (yes or no), chemotherapy (yes or no), radiotherapy (yes or no), hormonal therapy (yes or no) and trastuzumab
therapy (yes or no).
dWe added an interaction term between insurance type and reimbursement rate (as continuous variable) in the model, and reported the P value of the
interaction term as a significance test of the difference between HRs.
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insurances.16 Our data further illustrated the impact of public health
insurance status on breast cancer prognosis in developing countries
independent of clinical factors. Most importantly, in addition to insur-
ance status or type, we are the first to reveal that the low reimburse-
ment rate is associated with an excess risk of breast cancer-specific
mortality. In many developed countries, insurance plans usually come
with a fixed coinsurance or reimbursement rate. Our setting therefore
provides a unique opportunity to understand the potential mecha-
nisms underlying the relationship between insurance and cancer prog-
nosis, which highlights the urgent need of promoting reimbursement
rate in rural insurance schemes, to significantly improve breast cancer
prognosis and reduce health disparities at large.
Several mechanisms may contribute to the observed association of
suboptimal health insurance and compromised prognosis after a breast
cancer diagnosis. It is plausible that underinsured patients have limited
access to medical service, which may lead to delayed diagnosis and sub-
optimal treatment.19 This is also supported by our data that patients
insured by rural schemes or with low reimbursement rate were more
likely to have an advanced tumor stage and were less treated by radio-
therapy, hormonal therapy and trastuzumab, independent of tumor
characteristics and other types of treatment. In general, primary care is
less established in rural areas, and no organized screening program for
breast cancer is in place in Sichuan, which may result in delayed cancer
diagnosis among rural living women.19,23 Indeed, our analysis showed
that the associations between inadequate insurance and breast cancer-
specific mortality attenuated to some extent after adjusting for tumor
characteristics, suggesting the mediating role of more advanced tumor
stage. Moreover, underinsured patients face greater financial burden
and are less likely to afford out-of-pocket medical expenses for
advanced therapy.24 For instance, trastuzumab was not covered by the
insurances during the study period, and the high out-of-pocket medical
cost may prevent financially vulnerable patients from such therapy. In
line with that, our data indicated a further attenuated association after
controlling for cancer treatment, in support of the contribution of lim-
ited cancer care.
However, the increased risk of mortality among underinsured
patients with breast cancer is not entirely explained by the differential
tumor characteristics and treatment modes. In the present study, the
elevated risks of cancer-specific mortality remained robust, although
slightly attenuated, among patients insured by rural insurance schemes
or with low reimbursement rate, after exhaustive adjustment for clinical
factors. It is known that cancer diagnosis and treatment induce enor-
mous psychological stress in cancer patients.25 The financial hardship,
as a result of inadequate insurance, may add extra emotional turmoil to
cancer patients. A growing body of evidence from animal studies sug-
gests that psychological stress might modulate cancer progression
through facilitating tumor growth and invasion as well as inhibiting host
immune responses, operated by the hypothalamic-pituitary-adrenal
axis.26 It is not implausible that the lack of financial support may impact
breast cancer prognosis through psychological stress.
Our findings may partly reflect the difference of SES across rural
and urban regions as well as between individuals. Of note, SES is
highly correlated with, and to some extent reflected by, health
insurance status. As health insurance is likely underlying the causal
pathway between SES and cancer prognosis, we did not consider it as
a confounder in the studied association. However, we have ade-
quately addressed educational attainment (as a proxy for SES) in all
analyses. To further separate the influence of SES, we performed a
sensitivity analysis by conditioning on 88 residence areas to better
control for SES and accessibility to healthcare. Increased risks of
cancer-specific and overall mortality are still suggested, although some
are not significantly likely due to power issues. This largely refutes the
possibility that our findings are completely explained by the differen-
tial socioeconomic status.
One major merit of our study is the large-scale prospective cohort
design with virtually complete follow-up, largely limiting the common
sources of bias. The rich information on demographic and clinical char-
acteristics helped to disentangle the direct influence of health insurance
on cancer-specific mortality, from the influence through tumor charac-
teristics and treatment modes. Our study also has several limitations to
consider. First, some deaths due to other causes may be misclassified
as breast cancer-specific mortality. However, in our data, 297 out of
326 cancer-specific deaths (91.1%) entailed a clinically detected local
recurrence or distant metastasis, which largely alleviates such concerns.
Moreover, the 5-year breast cancer-specific survival rate in our cohort
is comparable to other Chinese cohorts27,28 and cohorts from devel-
oped countries,6,29 given a similar distribution of tumor stage. Further-
more, we have little information regarding extra insurances beyond the
basic/public insurance. However, there were only 11 patients with
commercial insurances included in our study and it is less likely to
impact our results. As this cohort is based on a regional medical center,
the findings may not be generalized to the entire population. The major
selection forces include urban and well-educated residents, as well as
advanced disease yet eligible for surgery and chemotherapy/radiother-
apy due to referrals from other hospitals. We, however, observed simi-
lar associations across regions of residence, educational levels, and
tumor stages (data not shown). We may also miss the patients that are
most financially vulnerable, because of the nature of our study setting.
Reassuringly, we noted the strongest association in the youngest
patients (aged 18-39 years), where we should have a smaller selection
force because young patients with breast cancer were more likely to
seek healthcare in a tertiary hospital.
In conclusion, our findings suggest that underinsured patients
face a higher risk of breast cancer-specific mortality in China, which
may provide fresh insights into the role of reimbursement rate in can-
cer health disparities in China and likewise developing countries.
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